TSLP and asthma: Human clinical trials of TSLP inhibition with the biologic tezepelumab completed to date have produced favourable results in patients with different asthma phenotypes, who experienced substantial improvements in lung function, symptom control and quality of life as well as reductions in exacerbation rates; this supported its recent approval for clinical practice in adults and adolescents with severe asthma [68].